- Report
- November 2023
- 630 Pages
Global
From €9124EUR$9,500USD£7,856GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- May 2020
- 482 Pages
Global
From €9124EUR$9,500USD£7,856GBP
- Report
- August 2018
- 16 Pages
Global
From €9605EUR$10,000USD£8,269GBP
- Report
- April 2021
- 191 Pages
Global
€21130EUR$22,000USD£18,192GBP
- Report
- April 2019
- 93 Pages
Global
From €3122EUR$3,250USD£2,687GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
Alunbrig is a type of lung cancer drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking certain proteins that help cancer cells grow and divide. Alunbrig is used in combination with other drugs to treat NSCLC that has spread to other parts of the body or that has not responded to other treatments. It is also used to treat NSCLC that has a certain genetic mutation.
Alunbrig is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is the first TKI approved for the treatment of NSCLC with a certain genetic mutation. Since its approval, Alunbrig has become an important part of the lung cancer drug market.
The Alunbrig market is highly competitive, with several companies offering similar drugs. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
